Core Viewpoint - Nuvectis Pharma, Inc. has made significant progress in its NXP900 development program during 2025, with multiple potential data readouts expected in 2026, while maintaining a focus on operational execution and financial responsibility [2]. Financial Results - As of December 31, 2025, the company's cash and cash equivalents increased to $31.6 million from $18.5 million in 2024, reflecting a rise of $13.1 million due to a public offering and access to an at-the-market facility, partially offset by operating expenses [3]. - The net loss for the year ended December 31, 2025, was $26.4 million, an increase of $7.4 million compared to a net loss of $19.0 million in 2024. This loss included $6.0 million in non-cash stock-based compensation and one-time license fees of $2.4 million [4]. - Research and development expenses for 2025 were $18.2 million, up from $12.9 million in 2024, marking an increase of $5.3 million. General and administrative expenses rose to $9.4 million from $6.9 million, an increase of $2.5 million [5]. - Finance income for 2025 was $1.1 million, compared to $0.8 million in 2024, reflecting an increase of $0.3 million [6]. Company Overview - Nuvectis Pharma, Inc. is focused on developing innovative precision medicines for serious unmet medical needs in oncology, with its primary asset being NXP900, an oral small molecule inhibitor targeting SRC Family Kinases [7].

Core Viewpoint - NorthStrive Biosciences Inc. has entered into a definitive exclusive license agreement with Modulant Biosciences LLC to develop and commercialize animal health products based on its EL-22 and EL-32 assets, marking a significant milestone for the company [1][6]. Group 1: License Agreement Details - The License Agreement grants Modulant an exclusive, royalty-bearing, sublicensable license to develop, manufacture, and commercialize products derived from EL-22 and EL-32 for non-human animal health applications, excluding the Republic of Korea [2]. - Modulant is responsible for all development, manufacturing, regulatory, and commercialization activities for the licensed products, with a focus on using commercially reasonable efforts [4]. - The agreement includes issued patents, pending patent applications, and associated proprietary know-how related to the EL-22 and EL-32 programs [4]. Group 2: Product and Market Implications - EL-22 and EL-32 target myostatin and activin-A pathways, which are crucial for muscle development, strength, and metabolic efficiency, and are increasingly important in animal health and nutrition applications [3]. - The collaboration aims to advance EL-22 and EL-32-derived products toward commercialization in the growing global animal health market, driven by rising demand for improved animal performance, wellness, and longevity [5]. Group 3: Company Background - NorthStrive Biosciences Inc. focuses on developing cutting-edge aesthetic medicines, with its lead asset EL-22 addressing muscle preservation during weight loss treatments [8]. - PMGC Holdings Inc., the parent company of NorthStrive, is a diversified holding company that seeks growth through strategic acquisitions and investments across various industries [9]. Group 4: Modulant Biosciences Overview - Modulant Biosciences LLC specializes in veterinary medicine innovation, focusing on developing novel drugs and biologics for various animal types, including livestock and companion animals [11].

Core Viewpoint - Geron Corporation is set to release its fourth quarter and full year 2025 financial results on February 25, 2026, and will host a conference call to discuss these results [1][2]. Company Overview - Geron Corporation is a commercial-stage biopharmaceutical company focused on changing the course of blood cancer [3]. - The company's first-in-class telomerase inhibitor, RYTELO (imetelstat), is approved in the United States and the European Union for treating certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) who have transfusion-dependent anemia [3]. - Geron is conducting a pivotal Phase 3 clinical trial of imetelstat in patients with JAK-inhibitor resistant/refractory myelofibrosis (R/R MF) and is also exploring its use in other hematologic malignancies [3]. - The mechanism of action involves inhibiting telomerase activity, which is elevated in malignant stem and progenitor cells in the bone marrow, potentially reducing proliferation and inducing death of malignant cells [3].

Core Insights - Royalty Pharma experienced a remarkable year in 2025, with a 16% growth in Portfolio Receipts, driven by a diversified portfolio and significant capital deployment [2][3][5] - The company returned a record amount of capital to shareholders and successfully internalized its external manager, enhancing its operational efficiency [2][5] - Looking ahead, Royalty Pharma anticipates a robust deal pipeline and multiple pivotal study results in 2026 that could unlock additional value [2][5] Financial Performance - Portfolio Receipts reached $874 million in Q4 2025, an 18% increase from Q4 2024, and totaled $3,254 million for FY 2025, reflecting a 16% growth year-over-year [5][6][53] - Royalty Receipts grew 17% to $856 million in Q4 2025 and 13% to $3,127 million for the full year, primarily driven by products like Voranigo, Trelegy, and Tremfya [6][14][53] - Net cash provided by operating activities was $827 million in Q4 2025 and $2,490 million for FY 2025, indicating strong operational cash flow [5][51] Capital Allocation and Shareholder Returns - The company deployed $2.6 billion in capital for royalty transactions in 2025, including a significant partnership for the therapy daraxonrasib [6][22] - Royalty Pharma repurchased 37 million Class A ordinary shares for $1.2 billion in 2025 and increased its quarterly dividend by 7% in Q1 2026 [6][16][17] - Full year 2026 guidance for Portfolio Receipts is projected to be between $3,275 million and $3,425 million, with expected growth in Royalty Receipts of 3% to 8% [5][8][9] Clinical and Regulatory Developments - Positive clinical updates were reported across the royalty portfolio in 2025, including FDA approvals for Myqorzo and Tremfya, and promising Phase 3 results for several therapies [4][6][29] - The company expects pivotal study results for daraxonrasib, pelacarsen, and litifilimab in 2026, which could further enhance its portfolio value [2][6][29] Liquidity and Financial Outlook - As of December 31, 2025, Royalty Pharma had cash and cash equivalents of $619 million and total debt of $9.2 billion [16][48] - The company anticipates interest payments of approximately $350 million to $360 million in 2026, with a decrease in operating costs as a percentage of Portfolio Receipts [9][10][16]

Adam Rogers, MD, President and Chief Executive Officer of NervGen to present and discuss clinical data from the Phase 1b/2a CONNECT SCI Study demonstrating durable improvement in function, independence, and quality of life in chronic spinal cord injury VANCOUVER, British Columbia, Feb. 11, 2026 (GLOBE NEWSWIRE) -- NervGen Pharma Corp. (“NervGen” or the “Company") (TSXV: NGEN) (NASDAQ: NGEN), a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord inj ...

Core Insights - Veru Inc. is advancing its Phase 2b PLATEAU clinical trial, which evaluates enobosarm in combination with semaglutide for older patients with obesity, set to initiate this quarter [1] - The company reported financial results for Q1 FY2026, showing a significant reduction in operating loss and net loss compared to the previous year [10][11] Clinical Development - The Phase 2b PLATEAU trial aims to address the weight loss plateau experienced by 88% of patients on GLP-1 receptor agonists, with enobosarm potentially aiding in fat loss while preserving lean mass [2][8] - Enobosarm has demonstrated the ability to burn fat and preserve muscle, which may help patients achieve incremental weight reduction beyond the plateau [2][3] - The trial will involve approximately 200 older patients (age ≥ 65) and will assess various endpoints including total body weight, fat mass, lean mass, physical function, and bone mineral density [7][8] Financial Performance - As of December 31, 2025, the company reported cash and cash equivalents of $33.0 million, a significant increase from $15.8 million at the end of September 2025 [10] - Research and development expenses decreased to $1.3 million from $5.7 million, while general and administrative expenses also saw a reduction [11] - The net loss for the first quarter was $5.3 million, or $0.26 per share, down from $8.9 million, or $0.61 per share in the same period last year [11][21] Regulatory Insights - The FDA has provided regulatory clarity for enobosarm in combination with GLP-1 RA, indicating two potential pathways for approval based on weight loss outcomes [4][5] - The FDA confirmed that enobosarm 3 mg is an acceptable dosage for future clinical development [5] Research Highlights - The Phase 2b QUALITY trial demonstrated that enobosarm combined with semaglutide led to greater fat loss while preserving lean mass, indicating a higher quality of weight reduction [3][14] - The FDA has recognized total hip bone mineral density as a validated surrogate endpoint for drug development in postmenopausal women with osteoporosis, which could be relevant for enobosarm's development [6]

Core Insights - Ribo Life Science and Ribocure Pharmaceuticals have entered into an exclusive global licensing agreement with Madrigal Pharmaceuticals for six pre-clinical siRNA programs targeting metabolic dysfunction-associated steatohepatitis (MASH) [1] - The collaboration will leverage Ribo's GalSTARTM platform to develop novel treatments for MASH, with options to expand into new siRNA programs [1] - Ribo will receive an upfront payment of US$60 million, with potential cumulative payments reaching US$4.4 billion based on milestone achievements, along with royalties on net sales [1] Company Overview - Suzhou Ribo Life Science Co., Ltd. is focused on developing nucleic acid drugs based on RNA interference technology, with a strong product pipeline aimed at addressing serious diseases with unmet medical needs [1] - Ribocure Pharmaceuticals, a subsidiary of Ribo, is dedicated to the global development of life-saving oligonucleotide therapies and innovative capacities for clinical trials [1] Industry Context - MASH is a serious liver disease that can lead to severe complications, including cirrhosis and liver cancer, and is a leading cause of liver transplantation [1] - The prevalence of MASH is increasing, with a significant rise in diagnosed patients expected, particularly those with moderate to advanced fibrosis [1] - Madrigal Pharmaceuticals has developed Rezdiffra, the first medication approved for treating MASH with moderate to advanced fibrosis, highlighting the high unmet medical need in this area [1]

Core Insights - Upstream Bio announced positive results from the Phase 2 VALIANT trial for verekitug, showing significant reductions in asthma exacerbation rates and improvements in lung function [2][3][4] Efficacy and Safety - Verekitug demonstrated a 56% reduction in annualized asthma exacerbation rate (AAER) at a dose of 100 mg every 12 weeks and a 39% reduction at 400 mg every 24 weeks compared to placebo [3] - Improvements in lung function were observed, with a placebo-adjusted increase in forced expiratory volume in one second (FEV1) of 122 mL for the 100 mg q12w group and 139 mL for the 400 mg q24w group [4] - The drug also significantly suppressed exhaled nitric oxide (FeNO), with reductions of 20.4 ppb and 26.3 ppb for the respective dosing regimens [4] Patient Enrollment and Future Trials - Over 90% of eligible patients from the VALIANT trial have transitioned to the Phase 2 VALOUR long-term extension study [8] - Upstream Bio plans to advance verekitug into Phase 3 trials for severe asthma and chronic rhinosinusitis with nasal polyps (CRSwNP) following regulatory interactions [6][9] Company Overview - Upstream Bio is focused on developing treatments for inflammatory diseases, particularly severe respiratory disorders, and is advancing verekitug as a unique antagonist targeting the TSLP receptor [19][12] - The company has conducted multiple Phase 2 trials for verekitug, including studies for chronic obstructive pulmonary disease (COPD) and CRSwNP, and is committed to addressing unmet needs in severe asthma treatment [18][19]

Core Viewpoint - Madrigal Pharmaceuticals has entered an exclusive global license agreement with Suzhou Ribo Life Science for six preclinical small interfering RNA (siRNA) programs aimed at treating metabolic dysfunction-associated steatohepatitis (MASH) [1][6] Company Overview - Madrigal Pharmaceuticals is focused on developing novel therapeutics for MASH, a liver disease with significant unmet medical needs [14] - The company’s lead product, Rezdiffra (resmetirom), is the first medication approved for MASH with moderate to advanced fibrosis [14] - Madrigal's pipeline now includes over 10 programs targeting various drivers of MASH, with Rezdiffra serving as the foundational therapy [2][3] Research and Development Strategy - The R&D strategy emphasizes innovative compounds targeting validated mechanisms of disease to improve patient outcomes [2] - siRNAs are highlighted for their precision in gene silencing, potentially complementing the effects of Rezdiffra [3][5] - The company plans to initiate IND-enabling activities for initial siRNA candidates in 2026 [5] Financial Aspects - Ribo will receive an upfront payment of $60 million, with potential cumulative payments reaching $4.4 billion based on milestone achievements, in addition to royalties on net sales [6] Market Context - MASH is a leading cause of liver transplantation, particularly among women, and is rapidly growing in prevalence [7][9] - Patients with moderate to advanced liver fibrosis face significantly higher risks of liver-related mortality, underscoring the urgency for effective treatments [8] Product Information - Rezdiffra is prescribed alongside diet and exercise for adults with MASH and is currently undergoing studies to confirm its clinical benefits [10]

Core Viewpoint - BioArctic AB will release its fourth quarter report for October - December 2025 on February 18, 2026, at 08:00 a.m. CET, followed by a presentation for investors, analysts, and media at 09:30 a.m. CET [1][2]. Company Information - BioArctic AB is a Swedish biopharma company focused on innovative treatments for neurodegenerative diseases, including Alzheimer's disease [2]. - The company developed Leqembi® (lecanemab), the first drug proven to slow the progression of early Alzheimer's disease and reduce cognitive impairment [2]. - BioArctic has a diverse research portfolio, including antibodies targeting Parkinson's disease and ALS, as well as additional Alzheimer's projects [2]. - The company utilizes its proprietary BrainTransporter™ technology to enhance treatment efficacy by transporting antibodies across the blood-brain barrier [2]. Event Details - The presentation on the fourth quarter report will include comments from CEO Gunilla Osswald and CFO Anders Martin-Löf, followed by a Q&A session [1]. - Participants can join via webcast or teleconference, with options to submit questions during the event [1][2].